IL2 and melanoma: However, when used at a low dose (1 x 106 IU/m2/day), IL-2 did not enhance the antitumor response in stage III/IV melanoma patients to a vaccine composed of the NY-ESO-1 CTA, the emulsifier Montanide, and CpG-B (99).